Immunocore (NASDAQ:IMCR) Downgraded to Hold Rating by Zacks Research

Immunocore (NASDAQ:IMCR) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Several other research analysts also recently commented on IMCR. Morgan Stanley lifted their target price on Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Mizuho set a $38.00 price objective on shares of Immunocore in a research report on Thursday, February 19th. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. UBS Group set a $55.00 target price on shares of Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company began coverage on shares of Immunocore in a research note on Friday, October 31st. They issued an “overweight” rating and a $60.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.30.

Immunocore Price Performance

NASDAQ:IMCR opened at $32.04 on Wednesday. The stock has a market capitalization of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. Immunocore has a 1-year low of $23.15 and a 1-year high of $40.71. The firm has a fifty day simple moving average of $33.55 and a 200 day simple moving average of $34.32. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). The firm had revenue of $104.48 million during the quarter, compared to analyst estimates of $145.48 million. Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.16%. The business’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) EPS. On average, research analysts expect that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Activity at Immunocore

In related news, insider David M. Berman sold 5,965 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $192,967.75. Following the transaction, the insider directly owned 5,859 shares in the company, valued at approximately $189,538.65. This represents a 50.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at $36,199.65. This trade represents a 47.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 19,137 shares of company stock worth $619,082. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new position in Immunocore in the 2nd quarter valued at $1,621,000. Acadian Asset Management LLC increased its position in shares of Immunocore by 392.3% in the second quarter. Acadian Asset Management LLC now owns 90,798 shares of the company’s stock worth $2,843,000 after purchasing an additional 72,355 shares during the period. Eschler Asset Management LLP acquired a new position in Immunocore in the second quarter valued at about $1,255,000. Frazier Life Sciences Management L.P. raised its stake in Immunocore by 27.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 384,782 shares of the company’s stock valued at $12,074,000 after purchasing an additional 83,612 shares in the last quarter. Finally, Fiera Capital Corp lifted its position in Immunocore by 1.0% during the second quarter. Fiera Capital Corp now owns 813,074 shares of the company’s stock worth $25,514,000 after purchasing an additional 7,924 shares during the period. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore News Roundup

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.